Beth Bioinformatics (BethBio)

Our recent article on predicting influenza virus evolution is now featured in Nature Communications Editors’ Highlights (nature.com/articles/s4146…) in the profile of Public Health.

BethBio announced that on March 2023, we have become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai. The company is working on new vaccine development with pharmaceutical companies using our novel solutions, such as viral mutation prediction and epitope screening.

A research project of real-time evaluation of COVID-19 vaccine effectiveness by the JC School of Public Health and Primary Care (JCSPHPC) is in discussion to be adopted by Singapore authorities to inform policy decision making. sphpc.cuhk.edu.hk/post/cuhk-expl…

2022/10/14 Healthcare Innovation and Technology Summit 2022(HITS 2022) was held in Hong Kong Science Park. Beth was invited as an exhibitor. We met plenty of industry leaders. Thank you for the speech given by Professor CHAN and Mr. Albret Wong. hkstp.org/our-community/… #HKSTP

5/ For @GaviSeth, increasing vaccine uptake requires a systems approach: “If we want to get universal health coverage, we need primary health care. Investing in vaccination is the most cost-effective way to improve primary health care and to reach zero-dose children.”

Enjoyed visiting the Adama Regional Vaccines Store in Ethiopia with Dr @lia_tadesse, and @dr_zelalem to get a better understanding of the supply chain processes, as well as vaccine logistics and any constraints impeding vaccine coverage. #VaccinesWork

No country in Europe has reached the 75% #flu vaccination target yet. We all have a role to play to increase flu vaccination uptake and protect people’s health bit.ly/3xXRIQ3 #WeWontRest

The immune responses and safety of fractional third-doses of heterologous COVID-19 vaccines after CoronaVac primary series news-medical.net/news/20221006/… @medrxivpreprint @mahidolpr @kkunews @thammasat_uni @ChulalongkornU #immune #COVID19 #coronavirus #covid #vaccine #vaccination

Grateful to join this collaborative piece & look into the cost-effectiveness of COVID-19 oral antiviral drugs in #HongKonger population :)

The @EMA_News has accepted a variation for the evaluation of a 50 µg #booster dose of the Omicron-containing bivalent COVID booster candidate, mRNA-1273.222, in adults 12 years and older. Read more: investors.modernatx.com/news/news-deta…

We and our partner @pfizer completed the regulatory submission for our #Omicron BA.4/BA.5-adapted bivalent #COVID19vaccine for children 5-11 years of age to @EMA_News - only a few days after the submission to @US_FDA.

The antibody response against SARS-CoV-2 in patients pre- and post-infusion with commercial intravenous immunoglobulin products news-medical.net/news/20220927/… @medrxivpreprint @ucl #antibody #SARSCoV2 #COVID19 #coronavirus #covid #infusion

Differences in protection from previous infection or vaccination against infection with Omicron BA.4/5 or BA.2 news-medical.net/news/20220927/… @medrxivpreprint @UMCUtrecht #vaccination #infection #Omicron #COVID19 #coronavirus #covid

Although vaccination is highly cost-effective, budgets for prevention are low across the EU. Increasing investment in vaccination could improve #VaccinesSupply and #access bit.ly/3BPiSLQ #RC6 #WeWontRest

NEW from our print issue #ICYMI: Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based #antibiotics and case their future into doubt. ow.ly/FS2K50KTgbX

Beautiful profile of Prof. Juliana Chan @CUHKMedicine just published in @DiabetesCareADA by @DrRonaldMa1 and colleagues. So grateful to have had the opportunity to train with a legendary figure in #diabetes research, care, and education! diabetesjournals.org/care/article/4…

We have published updated #COVID19 vaccine data supporting efficacy and safety in children from 6 months through 4 years of age. The updated analysis showed 73.2% vaccine efficacy and a favorable safety profile. investors.biontech.de/news-releases/…

We completed, together with @Pfizer, the submission to the @US_FDA requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children aged 5-11. investors.biontech.de/news-releases/…

An automated cold chain logistic center that SINOVAC donated to #VACSERA Egypt recently opened and the first batch of vaccines went into storage last Saturday. The facility can store 150 million doses and will contribute to the improvement of public health in #Egypt and #Africa.